-
Mashup Score: 8
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Episode 369: Paper of the Month with Bishoy Faltas by The Uromigos - 11 hour(s) ago
Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
Source: spotifycreators-web.app.linkCategories: General Medicine News, Hem/OncsTweet-
RT @Uromigos: @FaltasLab wins Paper of the Month for fascinating work on extrachromosomal DNA in #BladderCancer! https://t.co/a43aZYq0y0 ht…
-
-
Mashup Score: 3Episode 369: Paper of the Month with Bishoy Faltas by The Uromigos - 12 hour(s) ago
Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
Source: spotifycreators-web.app.linkCategories: General Medicine News, Hem/OncsTweet-
RT @Uromigos: @FaltasLab wins Paper of the Month for fascinating work on extrachromosomal DNA in #BladderCancer! https://t.co/a43aZYq0y0 ht…
-
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 2
About the survey This survey aims to evaluate oncologists’ attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in this survey is voluntary. The survey will take 10-15 minutes to complete; answers are recorded anonymously. Data will be processed to identify global trends in liquid biopsy adoption, shed light on region-specific challenges, and assess liquid biopsy’s perceived value in the treatment of solid tumors. The findings will guide strategies to improve the implementation and effectiveness of liquid biopsy in cancer care worldwide. Please complete the survey below. Thank you! The International Society of Liquid Biopsy Committee
Source: docs.google.comCategories: General Medicine News, Hem/OncsTweet-
ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy!! Open to all colleagues working with LB! 👏👏 https://t.co/tOs6CUCI0I
-
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 4
1 Washington University School of Medicine in St. Louis, St. Louis, MO, United States 2 Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States 3 College of Medicine, George Washington University, Washington, DC, United States 4 Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States 5 Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States 6 Department
Source: www.frontiersin.orgCategories: General Medicine News, Hem/OncsTweet-
RT @SbrtSean: https://t.co/UkwdPVVcyB
-
-
Mashup Score: 3Telix to Add FAP-Targeting Candidates to Theranostic Pipeline | Telix Pharmaceuticals - 6 day(s) ago
Our mission is to help patients with cancer live longer with better quality lives
Source: telixpharma.comCategories: General Medicine News, Hem/OncsTweet-
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline - Telix Pharmaceuticals https://t.co/t2rPG7XyYZ
-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy